LDL lowering effect of PCSK9 inhibition is reduced in women

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration, and its inhibition reduces the risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the sex-differential effect of either pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Myasoedova, Veronika A, Rimbert, Antoine, Camera, Marina, Le May, Cedric, Capoulade, Romain, Cariou, Bertrand, Poggio, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236513/
https://www.ncbi.nlm.nih.gov/pubmed/36722156
http://dx.doi.org/10.1093/ehjcvp/pvad009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236513/
https://www.ncbi.nlm.nih.gov/pubmed/36722156
http://dx.doi.org/10.1093/ehjcvp/pvad009

Ejemplares similares